Appendix F: Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology

CONTINUUM Lifelong Learning in Neurology

Volumn 13, Issue 1, 2007, Pages 193-199

  Miyasaki, J M ^a   Shannon, K ^b   Voon, V ^c   Ravina, B ^d   Kleiner Fisman, G ^e   Anderson, K ^f   Shulman, L M ^f   Gronseth, G ^g   Weiner, W J ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOZAPINE; DONEPEZIL; FLUOXETINE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PERGOLIDE; PIRACETAM; PRAMIPEXOLE; QUETIAPINE; RIVASTIGMINE; SERTRALINE;

AGRANULOCYTOSIS; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HAMILTON ANXIETY SCALE; HUMAN; LEWY BODY; MEDICAL PRACTICE; MEDLINE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; PSYCHOTHERAPY; SCREENING; THERAPY EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING; TREMOR; VOMITING;

EID: 33846870290     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.con.0000284562.79604.7f     Document Type: Article

References (35)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
2. Factor S, Weiner W. Parkinson's disease. Diagnosis and clinical management. New York: Demos, 2002.
3. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001;16:507-510.
4. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004;52:784-788.
5. Shulman LM, Taback EL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
6. Agid Y, Taquet H, Cesselin F, Epelbaum J, Javoy-Agid F. Neuropeptides and Parkinson's disease. Prog Brain Res 1986;66:107-116.
7. Dubois B, Hauw JJ, Ruberg M, Serdaru M, Javoy-Agid F, Agid Y. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation.] Rev Neurol (Paris) 1985;141:184-193.
8. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989;52:201-206.
9. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38:2-7.
10. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004;19:60-67.
11. Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000;15:1221-1224.
12. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatric Psychiatry 2000;15:644-649.
13. Naarding P, Leentjens AF, van Kooten F, Verhey FR. Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:329-334.
14. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998;21:280-284.
15. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999;28:39-43.
16. Neufeld MY, Blumen S, Aitkin I, Parmet Y, Korczyn AD. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia 1994;5:23-28.
17. Wermuth L, Sorensen P, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram. Nord J Psychiatry 1998;52:163-169.
18. Andersen J, Aabro E, Gulman N, Helmsted A, Pedersen H. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-Dopa. Acta Neurol Scand 1980;62:210-219.
19. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatric Psychiatry 2003;18:552-554.
20. Serrano-Duenas M. Dosis bajas de amitriptilina frente a dosis bajas de fluoxetine en el tratamiento de la depression de enfermos con Parkinson. Rev Neurol 2002;35:1010-1014).
21. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
22. Avilla A, Cardona X, Martin Baranera M, Maho P, Satre F, Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003;23:509-513.
23. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-1174.
24. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
25. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002;23:S89-90.
26. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.
27. Ondo W, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.
28. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomized, double-blind, placebo controlled, crossover study. JNNP 2006 (in press).
29. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
30. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
31. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
32. Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord 1990;5:230-234.
33. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
34. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005;13:844-851.
35. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.